{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:08:31Z","timestamp":1790784511364,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Nature Science Foundation of China","award":["81972550"],"award-info":[{"award-number":["81972550"]}]},{"name":"National Nature Science Foundation of China","award":["81372447"],"award-info":[{"award-number":["81372447"]}]},{"name":"National Nature Science Foundation of China","award":["LY22H160015"],"award-info":[{"award-number":["LY22H160015"]}]},{"name":"Zhejiang Provincial Basic Public Welfare Research Project","award":["81972550"],"award-info":[{"award-number":["81972550"]}]},{"name":"Zhejiang Provincial Basic Public Welfare Research Project","award":["81372447"],"award-info":[{"award-number":["81372447"]}]},{"name":"Zhejiang Provincial Basic Public Welfare Research Project","award":["LY22H160015"],"award-info":[{"award-number":["LY22H160015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Antibodies are considered highly specific therapeutic agents in cancer medicines, and numerous formats have been developed. Among them, bispecific antibodies (BsAbs) have gained a lot of attention as a next-generation strategy for cancer therapy. However, poor tumor penetration is a major challenge because of their large size and thus contributes to suboptimal responses within cancer cells. On the other hand, affibody molecules are a new class of engineered affinity proteins and have achieved several promising results with their applications in molecular imaging diagnostics and targeted tumor therapy. In this study, an alternative format for bispecific molecules was constructed and investigated, named ZLMP110-277 and ZLMP277-110, that targets Epstein-Barr virus latent membrane protein 1 (LMP1) and latent membrane protein 2 (LMP2). Surface plasmon resonance (SPR), indirect immunofluorescence assay, co-immunoprecipitation, and near-infrared (NIR) imaging clearly demonstrated that ZLMP110-277 and ZLMP277-110 have good binding affinity and specificity for both LMP1 and LMP2 in vitro and in vivo. Moreover, ZLMP110-277 and ZLMP277-110, especially ZLMP277-110, significantly reduced the cell viability of C666-1 and CNE-2Z as compared to their monospecific counterparts. ZLMP110-277 and ZLMP277-110 could inhibit phosphorylation of proteins modulated by the MEK\/ERK\/p90RSK signaling pathway, ultimately leading to suppression of oncogene nuclear translocations. Furthermore, ZLMP110-277 and ZLMP277-110 showed significant antitumor efficacy in nasopharyngeal carcinoma-bearing nude mice. Overall, our results demonstrated that ZLMP110-277 and ZLMP277-110, especially ZLMP277-110, are promising novel prognostic indicators for molecular imaging and targeted tumor therapy of EBV-associated nasopharyngeal carcinoma.<\/jats:p>","DOI":"10.3390\/ijms241210126","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T01:32:57Z","timestamp":1686792777000},"page":"10126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma"],"prefix":"10.3390","volume":"24","author":[{"given":"Saidu","family":"Kamara","sequence":"first","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Guo","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wen","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanli","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Damania, B., and Pipas, J.M. (2009). DNA Tumor Viruses, Springer.","DOI":"10.1007\/978-0-387-68945-6"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2012.01.004","article-title":"The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC)","volume":"22","author":"Dawson","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","first-page":"3","article-title":"Why and How Epstein-Barr Virus Was Discovered 50 Years Ago","volume":"Volume 390","author":"Epstein","year":"2015","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"ref_4","first-page":"581","article-title":"Epstein-Barr virus and nasopharyngeal carcinoma","volume":"33","author":"Young","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ijc.2910420305","article-title":"Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma","volume":"42","author":"Fu","year":"1988","journal-title":"Int. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1038\/sj.onc.1208846","article-title":"Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K","volume":"24","author":"Mainou","year":"2005","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2478\/s11658-008-0045-2","article-title":"The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer","volume":"14","author":"Pang","year":"2009","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ijrobp.2017.11.023","article-title":"Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients with Radiation-Induced Brain Necrosis","volume":"100","author":"Li","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41419-020-2410-7","article-title":"Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_11","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2011.09.003","article-title":"A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies","volume":"20","author":"Schaefer","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-11-0820","article-title":"Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3","volume":"11","author":"McDonagh","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-12-1611","article-title":"Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1535-7163.MCT-13-0255","article-title":"MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors","volume":"13","author":"Fitzgerald","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-19-1095","article-title":"Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3","volume":"19","author":"Rau","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1902034","DOI":"10.1080\/19420862.2021.1902034","article-title":"A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3","volume":"13","author":"Rau","year":"2021","journal-title":"mAbs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e97805","DOI":"10.1172\/jci.insight.97805","article-title":"TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies","volume":"3","author":"Ahmed","year":"2018","journal-title":"JCI Insight"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.intimp.2015.07.026","article-title":"Induction of protective and therapeutic anti-cancer immunity by using bispecific anti-idiotype antibody G22-I50 for nasopharyngeal carcinoma","volume":"28","author":"Wang","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00259-009-1123-z","article-title":"(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging","volume":"36","author":"Liu","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: Successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1074\/jbc.M111.311522","article-title":"Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains","volume":"287","author":"Hutt","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1745-7254.2005.00135.x","article-title":"Antibody engineering: Facing new challenges in cancer therapy","volume":"26","author":"Sanz","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prot.10169","article-title":"Anti-idiotypic protein domains selected from protein A-based affibody libraries","volume":"48","author":"Eklund","year":"2002","journal-title":"Proteins"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.biomaterials.2010.11.053","article-title":"Affibody-based nanoprobes for HER2-expressing cell and tumor imaging","volume":"32","author":"Gao","year":"2011","journal-title":"Biomaterials"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody Molecules in Biotechnological and Medical Applications","volume":"35","author":"Frejd","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cbic.200400388","article-title":"Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein","volume":"6","author":"Engfeldt","year":"2005","journal-title":"Chembiochem"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15226","DOI":"10.1038\/srep15226","article-title":"Affibody-mediated PET imaging of HER3 expression in malignant tumours","volume":"5","author":"Rosestedt","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nmat4476","article-title":"A small-molecule dye for NIR-II imaging","volume":"15","author":"Antaris","year":"2016","journal-title":"Nat. Mater."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11307-016-0980-7","article-title":"Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions","volume":"19","author":"Marra","year":"2017","journal-title":"Mol. Imaging Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3892\/ijo.2016.3721","article-title":"Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator","volume":"49","author":"Andersson","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/protein\/gzq118","article-title":"Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules","volume":"24","author":"Kronqvist","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.chembiol.2011.05.011","article-title":"The development of peptide-based tools for the analysis of angiogenesis","volume":"18","author":"Fedorova","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73995","DOI":"10.18632\/oncotarget.12174","article-title":"Generation of affibody molecules specific for HPV16 E7 recognition","volume":"7","author":"Xue","year":"2016","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1007\/s00253-021-11559-6","article-title":"Novel EBV LMP1 C-terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma","volume":"105","author":"Kamara","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbrc.2008.10.027","article-title":"Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line","volume":"377","author":"Ekerljung","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1042\/BA20090096","article-title":"Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule","volume":"54","author":"Friedman","year":"2009","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00253-008-1468-4","article-title":"Bifunctional enhancement of a beta-glucanase-xylanase fusion enzyme by optimization of peptide linkers","volume":"79","author":"Lu","year":"2008","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1074\/jbc.273.3.1496","article-title":"Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a\/p90rsk that are inducible by MAPK","volume":"273","author":"Dalby","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10637-005-2899-8","article-title":"Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer","volume":"23","author":"Yeon","year":"2005","journal-title":"Investig. New Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Cittera","year":"2003","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Wu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.febslet.2010.04.014","article-title":"Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications","volume":"584","author":"Feldwisch","year":"2010","journal-title":"FEBS Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cbpa.2009.04.627","article-title":"Engineered protein scaffolds as next-generation antibody therapeutics","volume":"13","author":"Gebauer","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1007\/s00253-018-9167-2","article-title":"Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer","volume":"102","author":"Zhu","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.7150\/thno.24607","article-title":"A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.ejca.2008.07.013","article-title":"Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition","volume":"44","author":"Bozec","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_53","first-page":"e2971","article-title":"Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma","volume":"10","author":"Maas","year":"2018","journal-title":"Cureus"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1758-3284-1-36","article-title":"HPV & head and neck cancer: A descriptive update","volume":"1","author":"Goon","year":"2009","journal-title":"Head Neck Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/375081a0","article-title":"Requirement of an ICE\/CED-3 protease for Fas\/APO-1-mediated apoptosis","volume":"375","author":"Los","year":"1995","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.2787530","article-title":"Monoclonal antibody-mediated tumor regression by induction of apoptosis","volume":"245","author":"Trauth","year":"1989","journal-title":"Science"},{"key":"ref_57","first-page":"87","article-title":"Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies","volume":"31","author":"Tatake","year":"1990","journal-title":"J. Clin. Lab. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/cmdc.200800122","article-title":"HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy","volume":"3","author":"Alexis","year":"2008","journal-title":"ChemMedChem"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1021\/acs.molpharmaceut.8b00393","article-title":"Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab","volume":"15","author":"Orlova","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-anchem-061516-045205","article-title":"Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis","volume":"10","author":"Yu","year":"2017","journal-title":"Annu. Rev. Anal. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:54:54Z","timestamp":1760126094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms241210126"],"URL":"https:\/\/doi.org\/10.3390\/ijms241210126","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}